Previous

ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
Next

Elevation Oncology Announces Pricing of $50 Million Public Offering